US SEC Filings Daily Market Digest — May 14, 2026

14-05-2026

DC Funds, LP filed its 13F-HR on May 14, 2026, disclosing equity holdings as of March 31, 2026, with a total portfolio market value of $1,485,900 across 3 positions, all held with sole voting power. Key holdings include Barinthus Biotherapeutics plc ADS (642,204 shares valued at $365,414), TScan Therapeutics Inc common stock (630,000 shares valued at $630,000), and Werewolf Therapeutics Inc common stock (589,102 shares valued at $490,486). No prior period comparisons are provided in the filing.

• · Period end date: March 31, 2026
• · Barinthus Biotherapeutics: 642,204 shares sole
• · TScan Therapeutics: 630,000 shares sole
• · Werewolf Therapeutics: 589,102 shares sole

14-05-2026

DC Investments Management, LLC filed its quarterly 13F-HR on May 14, 2026, reporting total equity holdings valued at $261,233,675 as of March 31, 2026, across 76 positions. The portfolio is heavily weighted toward the Vanguard FTSE All-World ex-US ETF ($122,427,309), followed by the SPDR S&P MidCap 400 ETF ($18,917,879) and Piedmont Realty Trust Inc. ($4,892,377). No option positions or voting authority deviations were reported.

• · Filing period end date: March 31, 2026
• · All positions held with sole discretionary voting authority (SH DFND 1)
• · No put or call options reported (all 0)

14-05-2026

Lord, Abbett & Co. LLC filed its 13F-HR on May 14, 2026, reporting equity and other securities holdings as of March 31, 2026, across 557 investment titles with a total market value of $30,630,739. Notable positions include Alphabet Inc. Cap Stk Com ($885,734), Broadcom Inc. ($514,820), Apple Inc. ($502,806), Exxon Mobil Corp. ($414,429), and Eli Lilly & Co. ($387,815). The filing provides a standard quarterly snapshot with no period-over-period comparisons available.

• · Report period end date: 2026-03-31
• · Filed as of date: 2026-05-14
• · SEC file number: 028-00413
• · Business address: 30 Hudson Street, Jersey City, NJ 07302
• · State of incorporation: DE

14-05-2026

Lifeway Foods reported record Q1 2026 net sales of $63.0 million, up 36.7% YoY from $46.1 million, driven by 37% volume-led growth in Lifeway Kefir and Farmer Cheese, with gross profit margin expanding 360 basis points to 27.5%. Net income rose 32% to $4.7 million ($0.30 diluted EPS), reflecting operational execution, though SG&A expenses increased 16.8% to $10.9 million amid marketing investments. The company drew $6.9 million on its line of credit to fund $11.0 million in capex, supporting growth outlook including $45-50 million Adjusted EBITDA target for FY2027.

• · Total assets increased to $120.5 million as of March 31, 2026 from $105.6 million at December 31, 2025.
• · Property, plant and equipment, net rose to $57.8 million from $48.3 million QoQ due to capex.
• · Net cash provided by operating activities was $4.4 million in Q1 2026 vs used $0.2 million in Q1 2025.
• · 26th consecutive quarter of year-over-year net sales growth.
• · Recognized as Dairy Foods' Processor of the Year 2025 and other awards.

14-05-2026

Vernal Capital Acquisition Corp., a blank check company, consummated its IPO on May 7, 2026, selling 10,000,000 public units at $10.00 each for $100,000,000 gross proceeds and 251,250 private units to sponsors for $2,512,500, depositing $100,500,000 into a trust account. The balance sheet as of May 7, 2026, shows total assets of $101,518,073, with $793,727 in shareholders' equity. However, the auditor's report raises substantial doubt about the company's ability to continue as a going concern if it fails to complete an initial business combination within 15 months (or up to 21 months if extended).

• · Cash outside trust: $943,073; cash held in trust for over-allotment: $75,000.
• · Over-allotment option liability: $135,280.
• · Founder shares retroactively restated: 2,875,000 issued to sponsors for $25,000, including up to 375,000 subject to forfeiture.
• · Business combination must have fair market value of at least 80% of trust assets (excluding deferred underwriting commissions and taxes).
• · IPO registration statement effective May 5, 2026; must complete business combination within 15 months from May 7, 2026 (or up to 21 months if extended).

14-05-2026

Lumen Technologies, Inc. (via subsidiaries Level 3 Parent, LLC and Level 3 Financing, Inc.) entered into a Third Amendment Agreement dated May 13, 2026, to its Credit Agreement, establishing $2,400,000,000 in Term B-5 Refinancing Loans to fully prepay existing Term B-4 Loans. The proceeds are advanced to Level 3 Communications, LLC and used alongside cash on hand for the refinancing. Additionally, administrative and collateral agents are transitioning from Wilmington Trust to Bank of America, N.A. and U.S. Bank Trust Company, National Association, respectively, with initial exclusions for guarantees and collateral from regulated subsidiaries pending permit conditions.

• · Amendment effective on Refinancing Effective Date, with Term B-5 Loans as Term SOFR Borrowing with initial Interest Period ending June 30, 2026.
• · Certain Term B-5 Lenders elect to convert existing Term B-4 Loans into Term B-5 Refinancing Loans.
• · Guarantees and collateral from Regulated Guarantor/Grantor Subsidiaries initially excluded for Term B-5 Obligations pending satisfaction of Term B-5 Guarantee Permit Condition and Term B-5 Collateral Permit Condition.
• · Administrative Agent transition effective Administrative Agency Transfer Effective Date; Collateral Agent transition effective Collateral Agency Transfer Effective Date.

14-05-2026

Intelligent Bio Solutions Inc. reported fiscal Q3 2026 revenue of $1,060,802, up 46% YoY from $728,867, driven by cartridge sales growth of 59% to $703,538 (66% of revenue) and other sales up 80% to $217,857, though reader sales declined 16% to $139,407. Nine-month revenue reached $3,069,373, up 39% YoY from $2,208,648, with gross margins expanding to 50.5% in Q3 (from 46.8%) and 49.3% for the nine months (up 800 basis points). Despite revenue gains, Q3 net loss widened to $2,869,640 from $2,550,674, reflecting higher operating expenses.

• · Cash and cash equivalents increased to $6,862,204 at March 31, 2026 from $740,371 at December 31, 2025.
• · Total assets $14,862,792 at March 31, 2026, up from $8,249,786 at June 30, 2025.
• · Q3 operating loss $2,947,101, wider than $2,560,329 YoY.
• · Nine-month operating expenses $10,584,443, up from $8,917,114 YoY.

14-05-2026

Onconetix, Inc. reported Q1 2026 progress at its subsidiary Proteomedix AG, including two new peer-reviewed publications reinforcing Proclarix®'s performance in reducing overdiagnosis and unnecessary biopsies in prostate cancer diagnosis, based on studies of 371 and 132 men respectively. The company initiated the multi-center PRIME validation study in the U.S. with Labcorp Holdings Inc., targeting up to 500 men with first participants enrolled. European commercial expansion advanced, with nearly 100 Proclarix® tests conducted in a UK screening initiative and new partnerships in Turkey.

• · First Proclarix publication (Schiess et al.) accepted in BMC Cancer, outperforming %fPSA and ERSPC risk calculator.
• · Second publication (Athanasiou et al.) in Cancers (2026, 18, 1348-62) on active surveillance patients.
• · Proclarix is CE-IVD certified and anticipated for U.S. as lab-developed test via Labcorp license.

14-05-2026

GP-Act III Acquisition Corp. (GPATU) passed a special shareholder resolution amending its Amended and Restated Memorandum and Articles of Association, extending the deadline to consummate a Business Combination from 24 months after IPO to November 13, 2026. This change to Articles 49.9 and 49.10 provides additional time to complete a merger and avoids immediate liquidation risk. No financial metrics or performance data were disclosed in the filing.

• · Filing items: 1.01, 5.03, 5.07, 9.01
• · Amendments specifically target Article 49.9 introduction and Article 49.10 wording
• · Effective immediately upon shareholder resolution

14-05-2026

Encore Capital Group, Inc. announced on May 12, 2026, its intention to offer €300.0 million aggregate principal amount of senior secured floating rate notes due 2033 in a private placement to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S. On May 13, 2026, the offering was upsized to €325.0 million, with interest accruing at three-month EURIBOR (subject to a 0% floor) plus 3.250% per annum, reset quarterly. The notes have not been and will not be registered under the Securities Act.

• · Offering conducted as private placement pursuant to Rule 144A and Regulation S.
• · Notes may not be offered or sold in the United States absent registration or exemption.

14-05-2026

News Corporation filed an 8-K disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, under which the company is authorized to acquire up to $1 billion in aggregate of its Class A common stock (NWSA) and Class B common stock (NWS). The disclosures, dated as noted in Exhibits 99.1 and 99.2, include daily transaction updates if any under the program, as required by ASX rules. No specific repurchase transactions are detailed in the filing body.

• · Filing date: May 14, 2026
• · Date of earliest event reported: May 13, 2026
• · Securities: Class A Common Stock (NWSA, par value $0.01), Class B Common Stock (NWS, par value $0.01), traded on Nasdaq Global Select Market

14-05-2026

Wayfair Inc. issued a press release on May 13, 2026, announcing the pricing by its subsidiary Wayfair LLC of a private offering of $400 million aggregate principal amount of 7.125% senior secured notes due 2034. The notes are being offered only to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S, and have not been registered under the Securities Act. There is no assurance that the issuance and sale will be consummated.

• · Notes and related guarantees not registered under the Securities Act of 1933
• · Offered only to persons reasonably believed to be qualified institutional buyers (Rule 144A) and non-U.S. persons (Regulation S)
• · Information in Item 7.01 and Exhibit 99.1 not deemed 'filed' under Section 18 of the Exchange Act

14-05-2026

Mercury General Corporation held its 2026 Annual Meeting of Shareholders on May 13, 2026, electing all nine director nominees with votes for ranging from 39,115,597 to 40,720,444 shares, though Martha E. Marcon faced the highest withheld votes at 1,810,103. Shareholders approved, on an advisory basis, named executive officer compensation (40,328,913 for, 568,701 against) and ratified KPMG LLP as independent auditor for the fiscal year ending December 31, 2026 (42,985,321 for, 511,025 against). Broker non-votes were consistent at 2,584,625 across director elections and compensation vote.

• · Meeting held on May 13, 2026; filing dated May 14, 2026
• · Auditor ratification for fiscal year ending December 31, 2026
• · Commission File No. 001-12257; I.R.S. Employer Identification No. 95-2211612

14-05-2026

AirSculpt Technologies, Inc. held its 2026 Annual Meeting on May 12, 2026, with 65,895,278 shares present or represented by proxy, equating to 93.49% quorum of 70,486,528 outstanding shares. Shareholders elected Adam Feinstein, Thomas Aaron, and Kenneth Higgins as Class II directors with For votes of 34,395,398, 34,394,367, and 33,801,294 respectively, but significant Withheld votes of 12,526,801 to 13,120,905 and 18,973,030 broker non-votes indicate notable opposition. Grant Thornton LLP was ratified as independent auditor for the year ending December 31, 2026, with 41,551,299 For votes but a substantial 24,343,978 Against.

• · Proposal 1 abstentions: 49 votes for each director nominee
• · Proposal 2 abstentions: 1 vote
• · No other matters voted on at the meeting
• · Proxy statement filed April 15, 2026

14-05-2026

Liberty Latin America Ltd. furnished an 8-K announcing that the financial report of its wholly-owned subsidiary Cable & Wireless Communications Limited (C&W) for the quarter ended March 31, 2026, was made available on the investor relations section of its website (www.lla.com) on May 13, 2026. This disclosure is pursuant to Item 7.01 (Regulation FD Disclosure) and is not deemed 'filed' for liability purposes. No specific financial metrics or performance details were included in the filing itself.

• · Securities: Class A Common Shares (LILA) and Class C Common Shares (LILAK) on NASDAQ Stock Market LLC
• · XBRL exhibits (101.SCH, 101.DEF, 101.LAB, 101.PRE, 104) included as financial data files

14-05-2026

Health In Tech, Inc. hosted a conference call on May 13, 2026, to discuss Q1 2026 financial and operating results for the quarter ended March 31, 2026, with full details in the upcoming Form 10-Q and earnings press release. The company highlighted its low market penetration (900 distribution partners out of over 1 million brokers) in the nearly $1 trillion self-funded stop loss insurance market and announced a $7 million PIPE in March 2026 to fund growth in sales distribution, carrier partners, and technology. Management emphasized scaling through broker network expansion and AI-powered platform eDYIBS amid strong fundamentals.

• · Conference call replay available on IR website for approximately 90 days
• · Form 10-Q for period ended March 31, 2026, to be filed with SEC
• · Transcript furnished as Exhibit 99.1

14-05-2026

FingerMotion, Inc., a Delaware corporation with operations in Singapore, entered into a Securities Purchase Agreement dated May 13, 2026, with certain buyers to issue and sell Notes in a private placement pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The Closing is scheduled for no later than the second Business Day after execution, subject to satisfaction of conditions. The agreement includes representations confirming no material adverse effects since the latest financial statements, compliance with laws, valid intellectual property, adequate insurance, and no undisclosed liabilities or litigation with material impact.

• · Commission payable to Weild & Co for the transaction.
• · No brokerage or finder's fees payable to others.
• · Company address: 111 Somerset Road, Level 3, Singapore.

14-05-2026

Gesher Acquisition Corp. II reported net income of $891,601 for the three months ended March 31, 2026, a significant YoY increase of 2,922% from $29,499, driven by higher interest income of $1,304,269 on Trust Account securities (up 1,047% YoY). However, general and administrative expenses rose sharply 390% YoY to $412,668, leading to a larger operating loss, while cash decreased 46% QoQ to $589,283 amid ongoing cash burn from operations. Marketable securities in the Trust Account grew slightly 0.9% QoQ to $150,028,760, but shareholders' deficit widened 9.7% QoQ to $(4,657,291).

• · Deferred underwriting fee remains at $5,031,250.
• · Basic and diluted net income per share for both Class A and Class B Ordinary Shares was $0.04 for Q1 2026, up from $0.00 in Q1 2025.
• · Net cash used in operating activities was $503,926 for Q1 2026, compared to $231,741 in Q1 2025.

14-05-2026

Sizzle Acquisition Corp. II reported net income of $1,602,289 for the three months ended March 31, 2026, compared to a $42,127 loss in Q1 2025, primarily due to $2,037,819 in interest income from the Trust Account, which grew QoQ to $239,045,028. However, operating loss widened to $435,530 from $42,127 YoY amid higher general and administrative costs, cash decreased QoQ by 19% to $653,383, and shareholders' deficit expanded to $10,569,580. Accrued expenses surged QoQ to $299,810.

• · Deferred underwriting fee of $10,950,000 remains outstanding.
• · Net cash used in operating activities: $151,741 for Q1 2026.
• · Basic and diluted EPS for Class A and Class B shares: $0.05 in Q1 2026 vs $0.00 / $(0.01) in Q1 2025.

14-05-2026

SUMA Acquisition Corp, a SPAC, reported its first post-IPO quarterly results for Q1 2026, with IPO proceeds funding a Trust Account of $172,819,182 from 17,250,000 redeemable Class A Ordinary Shares at $10.02 per share, and net income of $152,021 driven by $319,182 in interest income. However, the company recorded an operating loss of $167,161, leading to a shareholders' deficit of $5,854,258, up significantly from $4,096 at year-end 2025. Cash position improved to $1,167,663, supported by $174,375,000 in gross unit sales net of costs.

• · IPO Promissory Note – related party: $45,078 as of March 31, 2026 (down from $49,920 at Dec 31, 2025)
• · Accrued offering costs: $152,589 as of March 31, 2026
• · Net cash used in operating activities: $189,737 for the three months ended March 31, 2026
• · Basic and diluted net income per share: $0.02 for both redeemable and non-redeemable Class A Ordinary Shares
• · Trading symbols: SUMAU (Units), SUMA (Class A Ordinary Shares), SUMAR (Rights) on NASDAQ

14-05-2026

New Fortress Energy Inc. reported total revenues of $226,953 thousand for the three months ended March 31, 2026, down 52% YoY from $472,282 thousand, leading to a sharply wider operating loss of $(225,375) thousand and net loss of $(400,604) thousand (EPS $(1.40)) compared to $(175,426) thousand (EPS $(0.65)) in Q1 2025, driven by declines across revenue streams and spikes in transaction costs (+346%) and asset impairments. Operating cash use worsened to $(118,902) thousand from $(7,237) thousand, with cash and equivalents plus restricted cash falling to $189,881 thousand. However, the company holds a $10,304,872 thousand revenue backlog extending through 2030 and beyond.

• · Asset impairment expense surged to $61,864 thousand in Q1 2026 from $246 thousand YoY.
• · Cash, cash equivalents and restricted cash decreased by $167,061 thousand during Q1 2026.
• · Contract assets, net decreased to $20,113 thousand as of March 31, 2026 from $32,166 thousand at Dec 31, 2025.

14-05-2026

SpringBig Holdings, Inc. reported Q1 2026 net revenues of $5,444 thousand, down 1.3% YoY from $5,516 thousand, while gross profit declined 16.8% to $3,586 thousand due to higher cost of revenues rising 54.1% to $1,858 thousand. Operating expenses fell 21.4% YoY to $3,725 thousand, leading to a narrower net loss of $494 thousand versus $751 thousand in Q1 2025. Cash and total assets decreased QoQ to $1,271 thousand and $4,280 thousand respectively, with net cash used in operating activities worsening to $229 thousand from $86 thousand YoY.

• · Allowance for credit losses increased to $381 thousand from $300 thousand QoQ.
• · Stock-based compensation expense decreased to $71 thousand from $163 thousand YoY.
• · Long-term debt current portion $9,756 thousand at Mar 31 2026 (previously non-current).

14-05-2026

Jackson Acquisition Co II reported net income of $1,969,083 for Q1 2026, down 11.6% YoY from $2,227,401, primarily due to lower interest income of $2,137,355 (down 12.2% YoY) despite reduced G&A costs of $168,272 (down 18.3% YoY). The Trust Account grew slightly QoQ to $244,680,543 from $242,543,188, reflecting accretion on 23,000,000 redeemable Class A shares at $10.64 per share; however, cash balances declined 24.5% QoQ to $393,467 and shareholders' equity fell to $52,478 from $220,750 due to accretion charges.

• · Basic and diluted EPS for redeemable Class A shares: $0.07 in Q1 2026 (down from $0.08 YoY)
• · Net cash used in operating activities: $128,309 in Q1 2026 (improved from $193,398 YoY)
• · Entity is an Emerging Growth Company, Small Business, and Shell Company
• · Redemption value per share: $10.64 as of March 31, 2026 (up from $10.55 at Dec 31, 2025)

14-05-2026

Healthcare Triangle, Inc. (HCTI) reported Q1 2026 revenue of $9,855K, up 166% YoY from $3,704K, with gross margin expanding to $2,393K from $329K, partly due to the Teyame acquisition. However, net loss widened to $6,198K from $1,700K amid higher operating expenses ($6,016K vs $1,727K), a $2,435K negative fair value change, and increased cash burn in operations ($6,864K used vs $5,557K). Total assets surged to $80,162K from $22,736K at year-end 2025, bolstered by $41M Teyame acquisition and equity issuances, though cash declined to $4,315K QoQ.

• · Accounts receivable increased to $8,367K from $2,070K QoQ.
• · Intangible assets rose to $55,219K from $2,808K, primarily from Teyame acquisition.
• · Short-term borrowings stood at $9,088K as of March 31, 2026.
• · Common stock issuances included 55,682 shares for acquisition, 515,326 for cash, 451,437 for debt conversion, and 681,553 pursuant to financing.

14-05-2026

American Picture House Corp (APHP) reported Q1 2026 revenues of $1,220, up from $0 YoY, with operating expenses declining sharply to $114,238 from $475,918, resulting in a narrower net loss of $171,239 versus $488,837 YoY. However, total assets fell 9.6% QoQ to $1,361,034 from $1,505,916, primarily due to an 89.4% drop in accounts receivable to $121,816, and stockholders' deficit widened to $405,282 from $257,547. Cash and cash equivalents improved modestly to $22,338 QoQ from $124, supported by financing inflows, though net cash from operations remained negative at $12,949.

• · Produced and licensed content costs increased to $1,175,000 as of March 31, 2026 from $300,000 as of December 31, 2025.
• · Note payable increased to $256,746 from $115,000 QoQ.
• · Net cash flows from operating activities improved to -$12,949 from -$155,207 YoY.
• · Weighted average shares used in per share computation: 113,563,498 for Q1 2026 vs 112,399,325 for Q1 2025.

14-05-2026

D. Boral Acquisition I Corp., a SPAC, reported net income of $1,247,160 for the three months ended March 31, 2026, primarily from $1,373,487 in interest income on the Trust Account offsetting $126,327 in formation and operating expenses, with basic and diluted EPS of $0.04 for both redeemable and non-redeemable shares. The company completed its IPO, issuing 28,750,000 redeemable Class A ordinary shares and depositing $287,500,000 into the Trust Account, driving total assets to $289,665,641 from $185,954 as of December 31, 2025—a massive QoQ increase—while shareholders' equity flipped to a positive $734,954 from a $41,845 deficit. Cash outside the Trust increased to $513,684 from $25,000, though operating activities used $350,672 in cash.

• · Filing date: May 14, 2026
• · Net cash used in operating activities: $350,672
• · IPO-related non-cash items include $11,303,944 remeasurement of redeemable shares and $4,930,470 fair value of representative shares

14-05-2026

Silo Pharma, Inc. reported a net loss of $1,647,117 for the three months ended March 31, 2026, widening approximately 60% YoY from $1,031,437, primarily due to sharply higher research and development expenses of $1,013,265 (up 70% YoY) and a gross loss of $2,662 versus a $16,566 profit in the prior year, despite flat license fee revenue of $18,026. Total assets declined to $7,018,132 from $7,605,100 at December 31, 2025, with cash and equivalents at $3,902,514 (down QoQ), though net cash used in operating activities improved to $822,623 from $1,640,300 YoY. Stockholders' equity decreased to $5,681,836 amid increased shares outstanding to 16,266,593.

• · Crypto assets at fair value decreased to $173,462 from $221,817 QoQ.
• · Gross profit turned to a loss of $2,662 from $16,566 YoY due to higher cost of revenues $20,688 vs $1,460.
• · Common stock issued: 848,320 shares for future services ($250,000) and 2,100,000 shares for acquired technology ($714,000).
• · Intangible assets net $214,438 (license with 20-year life).
• · Net cash used in investing activities $23,563 in Q1 2026 vs provided $871,381 in Q1 2025.

14-05-2026

Total assets expanded 7.8% QoQ to $11,767,323 as of March 31, 2026 from $10,915,409 at December 31, 2025, supported by growth in real estate investments and unconsolidated affiliates to $4,243,275. Revenues rose 46.7% YoY to $96,925 for Q1 2026 versus $66,053 in Q1 2025, driving net income attributable to shareholders up 58.1% to $161,832; however, expenses more than doubled to $130,837 due to $22,734 in new impairment charges, elevated management fees, and performance allocations, while basic EPS dipped slightly to $0.21 from $0.22. Operating cash flow improved 48.2% YoY to $126,045, though heavy investing outflows of $718,419 reflected ongoing acquisitions and investments.

• · Distributions declared at $0.1875 gross per share in Q1 2026, up from $0.1750 in Q1 2025.
• · Proceeds from common shares issuance: $760,293 in Q1 2026 vs $709,891 in Q1 2025.
• · Common share repurchases: $133,435 in Q1 2026 vs $102,225 in Q1 2025.
• · Income from unconsolidated real estate affiliates: $204,851 in Q1 2026, up 87.4% YoY.

14-05-2026

BGSF, Inc.'s amended 10-Q for the thirteen weeks ended March 29, 2026 (Q1 2026) shows a stable ending allowance for credit losses at $1,156 thousand, up 15.6% YoY from $1,000 thousand, with provision expense down significantly to $96 thousand from $198 thousand. However, amounts written off increased to $130 thousand from $112 thousand, total receivables declined to $1,313 thousand from $1,458 thousand QoQ, and computer software amortization expense dropped to $133 thousand from $299 thousand YoY. Weighted-average common shares outstanding decreased slightly to 10,684 thousand from 10,954 thousand YoY.

• · CARES Act receivable reduced to $0 from $280 thousand QoQ.
• · Weighted average remaining contractual life of options decreased to 5.0 years from 5.2 years.
• · Total intrinsic value of options outstanding increased to $124 thousand from $52 thousand.

14-05-2026

New America Acquisition I Corp., a SPAC, reported net income of $2,059,655 for the three months ended March 31, 2026, driven by $3,002,063 in interest income from the trust account offsetting a $311,975 operating loss. Cash held in the trust account grew 0.87% to $348,919,571, contributing to total assets rising 0.84% to $350,360,414; however, operating cash declined 9.37% to $855,526, total liabilities more than doubled to $1,724,935, and shareholders' equity fell 35.02% to $578,883. Per share net income was $0.04 for both redeemable and non-redeemable shares.

• · Provision for income taxes: $630,433 for the three months ended March 31, 2026.
• · Net cash used in operating activities: $88,580 for the three months ended March 31, 2026.
• · Non-cash remeasurement of Class A common stock subject to possible redemption: $2,371,630.
• · Income tax payable increased to $862,975 as of March 31, 2026.
• · Accounts payable increased to $111,019 as of March 31, 2026.

14-05-2026

MSD Investment Corp.'s Q1 2026 10-Q shows total assets increasing 6.4% QoQ to $7,012,012, driven by non-controlled/non-affiliated investments rising 6.8% to $6,824,822, while total investment income grew 23.5% YoY to $164,562 and net investment income rose 23.9% to $80,819. However, net unrealized depreciation of $31,814 contributed to a slight 2.3% YoY decline in net increase from operations to $60,852 versus $62,271, leading to total net assets dipping 0.1% QoQ to $3,274,323 and NAV per share falling 0.6% to $23.58 from $23.71.

• · Distributions declared per common share: $0.57 (down from $0.65 YoY)
• · Earnings per share: $0.44 (down from $0.62 YoY)
• · Total expenses: $83,743 (up 23.1% YoY from $68,050)
• · Net cash used in operating activities: $(340,099)
• · Revolving credit facility: $580,000 (up from $160,000 QoQ)

14-05-2026

Launchpad Cadenza Acquisition Corp I reported net income of $1,726,095 for the three months ended March 31, 2026, driven by $2,033,672 in interest income primarily from the Trust Account, which grew to $232,265,476 from $230,231,978 at December 31, 2025. However, the company recorded an operating loss of $307,577 and cash decreased by $362,823 to $907,573 amid net cash used in operations of $344,060. Shareholders’ deficit widened slightly to $(9,880,345) due to accretion of $2,033,498 offsetting net income.

• · Due from Sponsor remained at $25,000 as of March 31, 2026.
• · Total liabilities increased to $11,124,152 from $11,058,234.
• · Net cash used in operating activities: $344,060; net cash used in financing activities: $18,763.

14-05-2026

Concord Acquisition Corp II reported a significantly reduced net loss of $87,322 for the three months ended March 31, 2026, compared to $990,974 in the prior year period, primarily due to lower operating costs of $313,561 (down 34% YoY) and net other income of $226,239 versus a net expense of $495,740. However, cash balance declined sharply 67% QoQ to $64,925 from $196,869, reflecting ongoing operating cash burn of $131,944, while stockholders' deficit widened slightly to $(8,833,732) from $(8,746,603). The cash held in Trust Account remained stable near $100,000, with only 8,550 Class A shares subject to redemption.

• · Warrant liability increased to $865,113 as of March 31, 2026 from $604,253 at December 31, 2025.
• · Capital Contribution Note fair value decreased to $1,470,193 from $1,956,685 QoQ.
• · Net cash used in operating activities improved to $131,944 from $690,796 YoY.

14-05-2026

For Q1 2026, BitGo Holdings reported revenue of $3,773,573, more than doubling 113% YoY from $1,774,664, driven by higher digital asset sales. However, total expenses rose to $3,793,477 (114% YoY), resulting in an operating loss of $19,904 versus a $2,349 profit in Q1 2025, and net loss widened to $60,673 (136% larger YoY) due to unrealized losses on digital assets. Total assets grew 30% QoQ to $5,892,241 as of March 31, 2026, bolstered by $174,285 net IPO proceeds and increased stablecoin holder deposits.

• · Cash and cash equivalents segregated for stablecoin holders increased to $4,392,828 from $3,313,527 QoQ.
• · Net cash provided by financing activities was $1,200,438 in Q1 2026, primarily from IPO and stablecoin deposits.
• · Weighted-average shares for Class A and B common stock: 98,409 thousand in Q1 2026.

14-05-2026

Apartment Income REIT, L.P. reported total revenues of $193,682 thousand for Q1 2026, down 4.8% YoY from $203,472 thousand, primarily due to lower rental and other property revenues of $189,260 thousand versus $198,927 thousand. The company posted a net loss of $28,959 thousand and EPS of $(0.20), swinging from a $40,162 thousand profit and $0.24 EPS in Q1 2025, amid higher other expenses and absence of prior-year gains on dispositions. However, net cash provided by operating activities rose sharply to $39,600 thousand from $8,302 thousand, and interest expense declined to $81,237 thousand from $93,837 thousand.

• · Non-recourse property debt, net remained flat QoQ at approximately $5,719,186 thousand.
• · Capital expenditures in Q1 2026 totaled $12,768 thousand, down from $24,714 thousand YoY.
• · Weighted-average common units outstanding – basic decreased to 151,017 from 153,344 YoY.

14-05-2026

For the three months ended March 31, 2026, Muzinich BDC, Inc. reported total investment income of $3,372,623, down 38% YoY from $5,479,989, primarily due to sharp declines in affiliated investment income, alongside net unrealized depreciation of $1,520,722 compared to $150,939 appreciation YoY, resulting in net increase in net assets from operations of $1,053,568 versus $4,430,636 prior year. However, net investment income remained positive at $2,574,290, expenses fell 33% YoY to $798,333, net assets grew to $138,430,762 (up 0.8% QoQ from $137,377,194), and NAV per share rose to $818.63 from $812.40 QoQ. No stockholder distributions were made in the period, unlike $450,654 YoY.

• · Aqua Leisure Recreation, LLC investments on non-accrual status, ceasing interest income recognition.
• · Cash and cash equivalents increased to $5,198,100 from $3,605,909 QoQ.
• · Credit facility borrowings increased to $80,250,000 from $77,850,000 QoQ.
• · No dividends or distributions paid in Q1 2026 (vs $450,654 or $2.67 per share YoY).
• · Several equity investments valued at $0 fair value, including Midwest Trading Group and QUEST JVCO.

14-05-2026

Swarmer, Inc reported Q1 2026 results with revenue declining 82% YoY to $20,325 from $110,704, resulting in a significantly widened net loss of $4.5M compared to $0.7M in Q1 2025, driven by sharply higher SG&A ($3.0M vs $0.3M) and R&D expenses ($1.5M vs $0.5M). However, the company completed its IPO raising $16.0M net proceeds and converted preferred stock, boosting cash to $23.5M (up 153% QoQ from $9.3M) and flipping shareholders' equity to a positive $23.5M from a $9.9M deficit.

• · Gross margin turned negative at $(19,599) in Q1 2026 vs positive $65,162 in Q1 2025.
• · Net cash used in operating activities increased to $4.3M in Q1 2026 from $0.7M in Q1 2025.
• · Deferred offering costs of $471,719 as of Dec 31, 2025 were reclassified upon IPO.

14-05-2026

CaliberCos Inc. reported Q1 2026 total revenues of $4,294 thousand, down 41% YoY from $7,261 thousand due to the absence of consolidated funds hospitality revenues ($0 vs. $3,919 thousand), leading to a larger net loss of $5,931 thousand versus $4,554 thousand in Q1 2025. However, total assets expanded 33% QoQ to $179,594 thousand as of March 31, 2026 from $135,396 thousand at year-end 2025, driven by real estate investments in consolidated funds ($51,079 thousand vs. $10,807 thousand) and VIE consolidations, while total stockholders' equity rose 48% QoQ to $38,715 thousand. Cash and restricted cash declined to $4,606 thousand from $6,016 thousand at period start, with operating cash use worsening to $2,635 thousand from $1,738 thousand YoY.

• · Basic and diluted net loss per share improved to $(0.52) from $(3.85) YoY, reflecting increased weighted average shares outstanding to 7,000 thousand from 1,146 thousand.
• · Notes payable, net decreased QoQ to $42,441 thousand from $46,347 thousand.
• · Consolidated funds notes payable increased to $66,520 thousand from $33,605 thousand.

14-05-2026

Karman Holdings Inc. reported Q1 2026 revenue of $151,210 up 51% YoY from $100,124, gross profit of $63,865 up 62% YoY, and net income of $7,794 versus a $4,798 loss in Q1 2025. The company acquired Seemann Composites and Materials Sciences for $210,150 cash plus $15,205 in stock, driving total assets to $1,417,738 from $1,104,096 QoQ and boosting goodwill and intangibles; however, this led to a $217,525 investing cash outflow and long-term notes payable surging to $752,180 from $495,312. Operating cash flow improved to $209 from $(13,584) YoY, with cash equivalents at $73,798.

• · Interest expense net $12,646 in Q1 2026 vs $11,373 in Q1 2025.
• · Contract assets increased to $169,370 from $156,298 QoQ.
• · Depreciation and amortization $13,776 operating + $16,633 cash flow adj in Q1 2026.

14-05-2026

Applied Energetics reported zero revenue for Q1 2026, down 100% YoY from $209,753, leading to an operating loss of $3,830,108 (up 23% YoY from $3,105,680) driven by higher G&A expenses ($3,282,788 vs $2,609,688). Net loss attributable to common stockholders widened to $3,816,224 ($0.02 per share) from $3,114,167 ($0.01 per share), while cash and equivalents fell 37% QoQ to $4,064,093 from $6,436,082 amid $2,296,313 cash used in operations. Total assets declined to $6,629,274 from $9,064,658 at year-end, with stockholders' equity dropping 32% to $5,115,996.

• · Net cash used in operating activities: $2,296,313 in Q1 2026 vs $1,731,610 in Q1 2025.
• · Stock-based compensation expense: $1,348,232 in Q1 2026 vs $991,793 in Q1 2025.
• · G&A expenses: $3,282,788 in Q1 2026, down from prior quarter but up YoY.
• · Property and equipment net: $1,222,287 as of March 31, 2026 (down from $1,267,037 Dec 31, 2025).

14-05-2026

For the six months ended March 31, 2026, Oaktree Strategic Credit Fund reported total investment income of $364,495, up 27.4% YoY from $286,237, and net investment income of $198,605, up 32.9% YoY from $149,459, driven by higher interest and fee income. However, net unrealized depreciation of $110,156 and realized losses of $21,487 led to a 48.4% YoY decline in net increase from operations to $66,953, resulting in total net assets falling 3.1% to $4,402,669 from $4,541,805 at September 30, 2025, with NAV per share dropping to $22.38 from $23.09. The three months ended March 31, 2026 saw a net decrease in net assets from operations of $10,065 versus a $52,900 gain YoY, amid significant share repurchases totaling over $500,000 net across classes.

• · Net cash used in operating activities was $261,995 for six months ended March 31, 2026, less negative than $959,824 YoY.
• · Share repurchases net: Class I ($332,019), Class S ($169,360) for six months ended March 31, 2026.
• · Credit facilities borrowings $990,600 offset by repayments $877,000 in financing activities.
• · Total liabilities increased 10.3% to $3,022,784 from $2,740,629.

14-05-2026

For the three months ended March 31, 2026, Apollo IG Core Replacement, L.P. reported no investment income and total expenses of $142, resulting in a net investment loss of $142, but achieved a net increase in partners' capital from operations of $4,151 driven by $4,293 in unrealized gains on investments in the Aggregators. Partners' capital grew 61% to $1,315,697 from $817,321 at December 31, 2025, primarily due to $506,000 in capital contributions, though offset by $11,775 in distributions. Total investments in the Aggregators at fair value stood at $1,315,840, representing 100.01% of partners' capital.

• · Net cash used in operating activities: $(501,340), offset by $501,346 from financing activities.
• · Cash paid for interest: $3.
• · Underlying Aggregator A net increase in partners' capital: $3,243; Aggregator B: $1,602; Total: $4,845.
• · Cost basis of investments in Aggregators: $1,306,607.

14-05-2026

Enovix reported Q1 FY2026 revenue of $7,600 up 49% YoY from $5,098, with gross profit surging 495% to $1,552 from $261 driven by improved margins. However, operating expenses rose 6% to $45,447, leading to a wider net loss of $38,260 (up 63% YoY from $23,510), and stockholders' equity declined 11% to $240,672. Cash and equivalents fell 16% to $88,751 from $106,014 at year-end amid $33,072 used in operations.

• · Net cash provided by investing activities: $18,330 (vs. $64,371 used YoY)
• · Interest expense: $7,008 (up from $1,716 YoY)
• · Stock-based compensation expense: $11,765 (in cash flow adjustments)
• · Weighted average shares outstanding: 217,371,926 (up from 203,328,890 YoY)
• · Cash paid for interest: $8,671 (up significantly from $128 YoY)

14-05-2026

StubHub Holdings reported Q1 2026 revenue of $446,045 thousand, up 12.2% YoY from $397,607 thousand, swinging to net income of $48,045 thousand from a $22,183 thousand loss, driven by lower interest expense and foreign currency gains. However, income from operations declined 3.7% to $25,829 thousand amid a 49.1% surge in general and administrative expenses to $105,645 thousand. Cash flow from operations more than doubled to $298,416 thousand YoY, boosting cash and equivalents to $1,526,237 thousand from $1,241,587 thousand at year-end.

• · Redeemable preferred stock decreased to $454,350 thousand (490,000 shares) from $758,027 thousand (794,893 shares) due to conversions to Class A common stock.
• · Long-term debt obligations slightly decreased to $1,496,227 thousand from $1,506,957 thousand.
• · Stock-based compensation expense increased to $37,729 thousand from $5,605 thousand YoY.
• · Payments due to buyers and sellers rose to $1,111,677 thousand from $845,892 thousand QoQ.

14-05-2026

Oaktree Gardens OLP, LLC's total investment income for the three months ended March 31, 2026 rose 17% YoY to $24,092, driven by higher interest income from non-control/non-affiliate investments (+18% to $22,767), with net investment income up 18% YoY to $13,531. However, net unrealized depreciation widened to $5,985 from $1,429 YoY, leading to a 20% YoY decline in net increase in net assets from operations to $8,054 and earnings per common unit falling to $0.36 from $0.46; over six months, operations were nearly flat at $21,813 versus $21,655 YoY. Balance sheet showed investments at fair value increasing to $934,496 from $912,864 at September 30, 2025 (QoQ +2.4%), but total assets dipped to $971,554 from $989,537 (-1.8%) and net assets to $450,472 from $452,469 (-0.4%), with NAV per unit at $20.10 versus $20.41.

• · Credit facility borrowings: net repayment of $17,500 QoQ to $511,000 from $528,500.
• · Distributions to unitholders for six months ended March 31, 2026: $28,700 versus $22,000 YoY.
• · Operating cash flow for six months: $30,761 provided versus $189,190 used YoY.
• · Common units issued during six months: 4,890 versus 89,600 YoY.

14-05-2026

On May 7, 2026, Presidio Production Company (NYSE: FTW) entered into purchase and sale agreements to acquire oil and gas properties in Oklahoma from Canyon Creek Energy – Arkoma, LLC, Alchemist Energy LeaseCo, LP, Pivotal Arkoma Basin II, LLC, and other sellers for total consideration of 2,173,913 shares of common stock and $60 million in cash, with the three main agreements valued at approximately $81 million of the $83 million total. The properties include oil and gas leases, mineral interests, and related hydrocarbon production rights. The transaction is expected to close early in the third quarter of 2026, subject to customary closing conditions with no assurance of completion.

• · Properties located in Oklahoma
• · Agreements include customary representations, warranties, covenants, termination rights, and indemnification provisions
• · Company to enter into registration rights agreements for Canyon Creek and Alchemist share considerations
• · Securities registered: Class A common stock (FTW) and Warrants (FTW WS) on NYSE

14-05-2026

Gemsstock Ltd. filed its 13F-HR report on May 14, 2026, disclosing $948797124 total portfolio value as of March 31, 2026, across 28 equity positions primarily in energy, gold/mining, and technology sectors. Top holdings by value include Equinox Gold Corp ($119759238), Gulfport Energy Corp ($107523471), and Amazon.com Inc ($60252511), with all positions reported as solely owned shares and no other investment types indicated. No period-over-period changes are detailed in this filing.

• · Filing CIK: 0001724140
• · Filer address: 4th Floor, 18 Henrietta Street, London X0 WC2E 8QH
• · All 28 positions reported as SH SOLE (sole voting and disposition power) with no puts, calls, or other manager categories
• · Business phone: 00442037405132

14-05-2026

Editas Medicine reported new preclinical data at the 2026 ASGCT Annual Meeting demonstrating that a single dose of EDIT-401 achieved 90% or greater mean LDL-C reduction in non-human primates, with durable effects through six months, moderate 10-40% functional editing of LDLR alleles, and a six-fold or greater mean increase in hepatic LDLR protein. The data showed a promising safety profile with no adverse observations at the 1.5 mg/kg dose and highest delivery in hepatocytes with undetectable oocyte delivery. Additional mouse data supports no dose adjustments needed for HeFH patients.

• · Dose levels evaluated: 1.5 mg/kg - 3.0 mg/kg
• · LDL-C lowering rapid and durable through approximately six months
• · No adverse clinical observations at therapeutically relevant dose (1.5 mg/kg)
• · Highest delivery of EDIT-401 in hepatocytes vs. other non-target tissues
• · Undetectable oocyte delivery
• · Mouse data: PK/PD of single dose EDIT-401(mu) in heterozygous Ldlr loss-of-function and wildtype mice

14-05-2026

VIVIC CORP reported no revenue for the three and nine months ended March 31, 2026, compared to zero revenue in the three months and $44,243 in the nine months of the prior year, resulting in a net loss of $51,815 for the quarter (vs $950,807 prior year, a 95.5% reduction in loss magnitude) and $552,765 for the nine months (vs $2,498,000 prior year, 77.9% smaller loss). Total assets declined 29.1% to $2,738,062 from $3,859,558 at June 30, 2025, driven by a sharp drop in cash to $13,985 from $41,903, while total liabilities decreased 36.1% to $1,311,393 and stockholders' equity fell to $1,426,669 from $1,807,191. Net cash used in operating activities improved to $304,578 from $511,134 over nine months, supported by financing inflows.

• · Share-based compensation for three months ended March 31, 2026: $8,500 (vs $829,292 prior year).
• · SBA loan payable unchanged at $87,500.
• · Property and equipment, net: $0 as of March 31, 2026 (vs $302 at June 30, 2025).
• · Inventory: $0 as of March 31, 2026 (vs $4,249 at June 30, 2025).

14-05-2026

Rhenman & Partners Asset Management AB filed its 13F-HR on May 14, 2026, disclosing equity holdings as of March 31, 2026, totaling $810,489,964 across 86 positions, primarily in healthcare, biotechnology, and pharmaceuticals sectors. Top holdings include Boston Scientific Corp ($39,218,750 for 625,000 shares), Regeneron Pharmaceuticals ($37,163,984 for 48,100 shares), Eli Lilly & Co ($31,010,046 for 33,715 shares), and CVS Health Corp ($24,167,430 for 336,500 shares). No period-over-period changes are provided in this filing.

• · All positions reported as sole investment discretion.
• · Filing CIK: 0001599882; SEC File Number: 028-15944.
• · Business address: Strandvagen 5A, Stockholm V7 11451, Sweden.